perspective you used to calculate the cost. You state that total NHS costs were estimated. Do you mean the patient does not have to pay a (small) part of the costs you included in the study? Results : I'm not sure you can start a sentence with numbers, if stated at the beginning of a sentence you need write it in full. Did you collect data on the mean cost of wound care or the "additional cost" of wound care? If you did not collect data on the additional cost of pressure ulcer treatment, the cost may be an overestimation of the real cost. Please clarify this issue further in the paper. Introduction p. 6, lines 26 and 27 and p. 25 table 1: the classification has also a category "Suspected deep tissue injury". How was this classified? Although published articles may be limited, please add a paragraph that summarises the results (and limitations) of the available evidence on the cost of pressure ulcer treatment in the UK (for example Bennet et al 2004, ) and the cost of pressure ulcer treatment in community care (for example Foglia et al 2012 , Agreda et al 2007 , Severens et al. 2002 .
Methods
The paper should provide more details on the specific methodology on the cost-part of the study: the design of the cost study, the perspective of the study, the cost data that were collected, the source of these cost data and what costs data were not included (for example secondary prevention). How were total costs calculated? Some of these data are described further in the paper (Results and Discussion), but it should be clearly and detailed described in the method section. Describe in detail the type of costs you included, the clinical outcomes, the wound related health care resources and add an overview (table) . What was the rationale of excluding patients who died within a year of the diagnosis of their wound? Please add a statement.
Ethical approval: were THIN records anonymous? Results All included patients had only one pressure ulcer. This seems very unrealistic. You should address this limitation more thoroughly in the discussion part: is the THIN database reliable, what is the impact on the estimated costs, what is the impact on the healing rates and healing times. I suggest to include this item in the sensitivity analyses based on the UK prevalence figures. Please add the PU prevalence of the cohort in the text (not only in a table). If you mention "significant" or "not significant" please always add pvalues. Not all percentages should be included in the text (too much details). You can retain the most important and refer to the tables for less important results. For example: "None of the patients included in this study were recorded as having a hospital-acquired pressure ulcer. (exclusion criterion? ) However, 35% of patients acquired their wound within 3 months of hospital discharge of which 17% occurred within a month of discharge, 9% within 1-2 months and 10% within 2-3 months. 65% of patients had no history of a hospital admission in their record." p. 10 lines 17-18: "none of the patients were recorded as having a HA PU": I think this was an exclusion criterion? If so, this should not be included in the results. Not sure that non-UK readers know the difference between district nurses and practice nurses. Please clarify in the method section. p. 12 lines 21-24: I suggest you rephrase the sentence on mortality, because patients who died within 12 months were not included in the study (only survivors were included). p. 12 lines 48 -52, 55: if there was no significant difference between groups, I suggest you would not use the term "delayed". p. 12 52-57 Significant differences? P13, line 4: systemic anti-infectives (what type of anti-infectives were included): please clarify in the method section. P13. Line26: "unhealed PU" do you mean "unhealed in 12 months"? p. 13, lines 29-31: The part on costs that were not included in the total cost of pressure ulcer treatment should be placed in the method section. p. 14 lines 18-20: how long were anti-infectives provided? p. 14 lines 30-32: "The PU healing rate was lower among patients with a putative infection, and the mean time to healing was longer": please add p-values. Discussion p. 6, lines 16-19: the authors state that it is the first study on how PU are diagnosed. To my understanding, the absence of a correct PU diagnosis is a major limitation of this study: only one PU diagnosed per patient, no clear definition ( + differentiation with other wounds), at least half considered to be at risk of infection or infected (including 18% of all category I PU), prescribed dressing not suitable for type of injury (for example hydrogel for non-blanchable erythema talble 4), etc. Although the authors address some of these issues in their discussion, I think it should be added to the "Strengths and limitations of the study" section p. 2. Also add a paragraph about the implications on clinical practice related to these incorrect PU diagnoses: is it a sign of under registration, lack of knowledge on PU classification system and/or PU treatment p.19, line 32: was the cost of PU debridement included? Please add clarify in the method section. Graphs and Tables  Figure 4c: Is an anti-microbial not always an anti-infective? I suggest to use anti-infective and delete antimicrobial. Table 5 and Table 6 : I suggest to use the same order in the left column "resource use"
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07-Mar-2018
Dear Dr. Guest:
Manuscript ID bmjopen-2018-021769 entitled "PRESSURE ULCER MANAGEMENT IN CLINICAL PRACTICE IN THE UK: COSTS AND OUTCOMES" which you submitted to BMJ Open, has been reviewed. The comments of the reviewers are included at the bottom of this letter. The Editorial Office have also checked your manuscript for any minor formatting issues and these will be listed at the end of this email.
The reviewers have recommended revisions to your manuscript. Therefore, I invite you to respond to the reviewers' comments and revise your manuscript. Please remember that the reviewers' comments and the previous drafts of your manuscript will be published as supplementary information alongside the final version.
Editorial Requests:
• Please revise your title to indicate the research question, study design, and setting. This is the preferred format of the journal. The title has been amended.
• Can you please improve the abstract >> methods section? It should be more informative and more detailed. The abstract has been amended.
• Please shorten the 'Strengths and Limitations' section on page 2. This section should contain up to five short bullet points, no longer than one sentence each, that relate specifically to the methods or design of the study reported (see: http://bmjopen.bmj.com/site/about/guidelines.xhtml#articletypes). You can elaborate further on each point in the discussion section. This section has been amended.
• Re the author contributions section on page 4. Can you please revise this section so it aligns with the ICMJE criteria for authorship? For example, were all authors involved in revising the manuscript and gave final approval? Please see: http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authorsand-contributors.html This section has been amended.
•
The data sharing statement also needs revising to clarify how others can access the dataset underlying your results. For example is it available upon request from the corresponding author? Are there any ethical or legal restrictions to accessing the dataset? The data sharing statement has been amended.
The methods section of the main manuscript is also very brief. Please go through methods section of the STROBE checklist and check that all relevant items are reported in the paper. The methods should be written in enough detail so that other researchers would be able to reproduce your work. The Methods section has been expanded.
• Please also complete and include the most appropriate EQUATOR reporting guideline for this study design. Please see: http://www.equator-network.org/ Guideline has been included in the submission Excellent Comprehensive study about this important subject from UK, and showing that all the medical, nursing and allied help staff are concerned about pressure injury to the skin and how much can cause lost of function to the patient and financial cost to the health system. Few remarks i would like to ask:
• why the author used category instead of stage, which i think it is used all over the medical field? The latest EPUAP, NPUAP and PPPIA guidelines (2014) both refer to Category of pressure ulcer as does the NICE Quality Standard (QS89) 2015. Category is therefore the correct terminology.
• why the BMI used as an important factor in healing pressure ulcers? We previously showed that nutritional deficiency was an independent risk factor for non-healing of wounds (Odds ratio: 0.53 (95% CI 0.41 to 0.70); p<0.001) [BMJ Open. 2015; 5(12):e009283. doi:10.1136 /bmjopen-2015 , so this was explored further in this study.
• you considered the infection in relation to wound healing thats very good • I would like to see other factors mentioned in the article in relation to wound healing, example total protein and pre-albumin, patient diet, is the patient sitting all times or limited? is the patient in a special bed and what is the location of the ulcers This information was not routinely documented in the patients' records in the THIN database, so to include any of it would generate too much uncertainty.
• this study and the cost of healing pressure ulcers represents not in a hospital care or surgery. This study was limited to estimating the cost of patient management following initial presentation in the community.
Reviewer: 2 Reviewer Name: L. Demarré Institution and Country: AZ Sint-Elisabeth Zottegem, Belgium Competing Interests: None Comments below also included in file attached.
• Title: Add the chosen population in the title: community care The title has been amended. Abstract • Method: you need to add some information on the type of sampling method you used, which patients you included in the cohort, what type of cost study you performed and what health economic perspective you used to calculate the cost. You state that total NHS costs were estimated. Do you mean the patient does not have to pay a (small) part of the costs you included in the study? Patients do not pay for healthcare within the UK's NHS. It's free at the point of delivery. The Authors consider the abstract to be sufficiently self-explanatory bearing in mind the limitation on the number of words.
• Abstract Results : I'm not sure you can start a sentence with numbers, if stated at the beginning of a sentence you need write it in full. Editor please advise.
• Did you collect data on the mean cost of wound care or the "additional cost" of wound care? If you did not collect data on the additional cost of pressure ulcer treatment, the cost may be an overestimation of the real cost. Please clarify this issue further in the paper. The study only considers the cost of patient management attributable to a PU and does not estimate patients' overall healthcare costs. This has been inserted in the Methods. Introduction • p. 6, lines 26 and 27 and p. 25 table 1: the classification has also a category "Suspected deep tissue injury". How was this classified? The patient's records did not contain reference to a "Suspected deep tissue injury". Although this classification is included in the guidelines it is only an optional category in the UK and does not form part of reporting standards within the UK.
• Although published articles may be limited, please add a paragraph that summarises the results (and limitations) of the available evidence on the cost of pressure ulcer treatment in the UK (for example Bennet et al 2004) and the cost of pressure ulcer treatment in community care (for example Foglia et al 2012 , Agreda et al 2007 , Severens et al. 2002 . The Bennett study is summarised in the Discussion in the context of our results. The Foglia et al study takes a very narrow perspective and only estimates costs over a 30 day period which is not appropriate when considering a chronic condition like a pressure ulcer. If this data was used to inform clinical decision making it has the potential to lead to the wrong decision being made. So it was excluded from our article. The Authors have been unable to find the Agreda study (except the abstract), but the Severens study is now >18 years old and therefore no longer has any relevance since patient pathways, reimbursement and costs have changed substantially over this period. Methods • The paper should provide more details on the specific methodology on the cost-part of the study: the design of the cost study, the perspective of the study, the cost data that were collected, the source of these cost data and what costs data were not included (for example secondary prevention). The Methods has been amended but it already states the source of the cost data.
• How were total costs calculated? Some of these data are described further in the paper (Results and Discussion), but it should be clearly and detailed described in the method section. This has already been stated in the Methods.
• Describe in detail the type of costs you included, the clinical outcomes, the wound related health care resources and add an overview (table) . This information has been included in the text. The Authors do not consider a Table is necessary as this information is presented in Tables 5, 6 and 7.
• What was the rationale of excluding patients who died within a year of the diagnosis of their wound? Please add a statement. A statement has now been included.
• Ethical approval: were THIN records anonymous? This statement has been amended. Results • All included patients had only one pressure ulcer. This seems very unrealistic. You should address this limitation more thoroughly in the discussion part: is the THIN database reliable, what is the impact on the estimated costs, what is the impact on the healing rates and healing times. It was a surprising finding that the patients' records do not directly refer to multiple pressure ulcers. The Authors accept that some patients may have had more than one pressure ulcer, but this data was not accurately or consistently documented. However, in many ways the number of wounds per se is extraneous as we are not addressing the cost of treating a wound, but the cost of managing a patient with a pressure ulcer until the healing of the "last" wound. This has now been included as a study limitation. I suggest to include this item in the sensitivity analyses based on the UK prevalence figures. To include this as a sensitivity analysis would require too many assumptions which would create unnecessary uncertainty. Hence, it was decided not to included multiple PUs in a sensitivity analysis.
• Please add the PU prevalence of the cohort in the text (not only in a table). This has now been included.
• If you mention "significant" or "not significant" please always add p-values. A statement The p values <0.05 were considered statistically significant and have been reported. All p values ≥0.05 were not considered to be statistically significant and these numerical values have not been reported. This statement has now been included in the Methods.
• Not all percentages should be included in the text (too much details). You can retain the most important and refer to the tables for less important results. For example: "None of the patients included in this study were recorded as having a hospital-acquired pressure ulcer. (exclusion criterion? ) However, 35% of patients acquired their wound within 3 months of hospital discharge of which 17% occurred within a month of discharge, 9% within 1-2 months and 10% within 2-3 months. 65% of patients had no history of a hospital admission in their record." Repetition has been removed and percentages have only been reported in the text if they are not cited in Tables. • p. 10 lines 17-18: "none of the patients were recorded as having a HA PU": I think this was an exclusion criterion? If so, this should not be included in the results. This has now been removed from the Results.
• Not sure that non-UK readers know the difference between district nurses and practice nurses. Please clarify in the method section. This has now been clarified in the Methods.
• p. 12 lines 21-24: I suggest you rephrase the sentence on mortality, because patients who died within 12 months were not included in the study (only survivors were included). This has now been edited.
• p. 12 lines 48 -52, 55: if there was no significant difference between groups, I suggest you would not use the term "delayed". The term has been replaced.
• p. 12 52-57 Significant differences? It is unclear what the reviewer is referring to. • P13, line 4: systemic anti-infectives (what type of anti-infectives were included): please clarify in the method section.
• P13. Line26: "unhealed PU" do you mean "unhealed in 12 months"? The text has been changed.
• p. 13, lines 29-31: The part on costs that were not included in the total cost of pressure ulcer treatment should be placed in the method section. The text has been amended.
• p. 14 lines 18-20: how long were anti-infectives provided? Mean of 1.4 months per patient. This has now been included in the text.
• p. 14 lines 30-32: "The PU healing rate was lower among patients with a putative infection, and the mean time to healing was longer": please add p-values. These have now been added. Discussion • p. 6, lines 16-19: the authors state that it is the first study on how PU are diagnosed. To my understanding, the absence of a correct PU diagnosis is a major limitation of this study: only one PU diagnosed per patient, no clear definition ( + differentiation with other wounds), at least half considered to be at risk of infection or infected (including 18% of all category I PU), prescribed dressing not suitable for type of injury (for example hydrogel for non-blanchable erythema talble 4), etc. Although the authors address some of these issues in their discussion, I think it should be added to the "Strengths and limitations of the study" section p. 2. This has now been added to the Strengths and Limitations section.
• Also add a paragraph about the implications on clinical practice related to these incorrect PU diagnoses: is it a sign of under registration, lack of knowledge on PU classification system and/or PU treatment This has now been included under Study Limitations.
• p.19, line 32: was the cost of PU debridement included? Please add clarify in the method section. The incremental cost of debridement was £0 as it was principally nurse time and that has already been included in the analysis. Graphs and Tables  •  Figure 4c : Is an anti-microbial not always an anti-infective? I suggest to use anti-infective and delete antimicrobial. Figure 4 is correct as antimicrobial is a dressing and anti-infective is a systemic preparation (as described in the Figure title).
• Table 5 and Table 6 : I suggest to use the same order in the left column "resource use" Table  5 has been re-ordered. GENERAL COMMENTS its a good article dealing with a very important issue and after corrections some of the issues i think will be okay.
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